Sun Sue Yazaki, Melamed Alexander, Goldstein Donald P, Bernstein Marilyn R, Horowitz Neil S, Moron Antonio Fernandes, Maestá Izildinha, Braga Antonio, Berkowitz Ross S
Department of Obstetrics, Paulista School of Medicine, UNIFESP - São Paulo Federal University, São Paulo, SP, Brazil; Trophoblastic Disease Center of São Paulo Hospital, Paulista School of Medicine, UNIFESP - São Paulo Federal University, São Paulo, SP, Brazil.
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, USA; New England Trophoblastic Disease Center, Donald P. Goldstein, MD. Trophoblastic Tumor Registry, Boston, USA; Dana Farber Cancer Institute/Harvard Cancer Center, Boston, USA; Harvard Medical School, Boston, USA.
Gynecol Oncol. 2015 Jul;138(1):46-9. doi: 10.1016/j.ygyno.2015.05.002. Epub 2015 May 10.
To compare the clinical presentation and incidence of postmolar gestational trophoblastic neoplasia (GTN) among recent (1994-2013) and historical (1988-1993) cases of complete hydatidiform mole (CHM).
This study included two non-concurrent cohorts (1988-1993 versus 1994-2013) of patients from the New England Trophoblastic Disease Center (NETDC). Clinical and pathologic reports of patients diagnosed with CHM between 1994 and 2013 were reviewed. Gestational age at evacuation, features of clinical presentation, human chorionic gonadotropin (hCG) levels, and the rate of progression to GTN were compared.
In the current cohort (1994 to 2013) the median gestational age at diagnosis continued to decline compared to our prior cohort (1988-1993) (9weeks versus 12weeks). Patients from the current cohort were significantly more likely to be diagnosed prior to the 11th week of gestation (56 versus 41%, p=0.04). Patients in the current cohort were also significantly less likely to present with vaginal bleeding (46 versus 84%, p<0.001). Earlier diagnosis of complete mole did not result in a decrease in the rate of postmolar GTN. The frequencies of postmolar GTN in the current (1994-2013) and prior (1988-1993) cohorts were 19 and 23%, respectively. In the current cohort, even diagnosis prior to ten weeks gestation did not decrease the risk of developing GTN.
This study indicates that complete mole continues to be diagnosed progressively earlier resulting in a further decrease in some classical presenting symptoms. However, despite earlier detection, the risk of development of postmolar GTN has not been affected.
比较近期(1994 - 2013年)和历史时期(1988 - 1993年)完全性葡萄胎(CHM)患者中磨牙后妊娠滋养细胞肿瘤(GTN)的临床表现及发病率。
本研究纳入了新英格兰滋养细胞疾病中心(NETDC)的两个非同期队列(1988 - 1993年与1994 - 2013年)的患者。回顾了1994年至2013年间诊断为CHM的患者的临床和病理报告。比较了清宫时的孕周、临床表现特征、人绒毛膜促性腺激素(hCG)水平以及进展为GTN的比率。
与之前的队列(1988 - 1993年)相比,当前队列(1994年至2013年)诊断时的中位孕周持续下降(9周对12周)。当前队列中的患者在妊娠第11周之前被诊断的可能性显著更高(56%对41%,p = 0.04)。当前队列中的患者出现阴道出血的可能性也显著更低(46%对84%,p < 0.001)。完全性葡萄胎的早期诊断并未导致磨牙后GTN发生率降低。当前(1994 - 2013年)和之前(1988 - 1993年)队列中磨牙后GTN的发生率分别为19%和23%。在当前队列中,即使在妊娠10周前诊断也未降低发生GTN的风险。
本研究表明,完全性葡萄胎的诊断持续提前,导致一些经典症状进一步减少。然而,尽管检测提前,但磨牙后GTN的发生风险并未受到影响。